Pfizer

This study looks at health records of over 800,000 adults to see if the PCV20 vaccine reduces pneumonia cases. Researchers will compare pneumonia rates in people who got the vaccine versus those who did not. The goal is to measure how effective PCV20 is in adults aged 18 and olde…

This study tests a new pneumococcal vaccine (PG4) to see if it is safe and tolerable in adults. About 380 healthy adults will receive either the experimental vaccine, a similar vaccine, a standard vaccine, or a placebo. Participants will be monitored for side effects and give blo…

This study examines how well the ABRYSVO vaccine works when given during pregnancy to prevent RSV in infants. Researchers will compare health outcomes of babies born to vaccinated mothers versus unvaccinated mothers using electronic medical records. The goal is to see if the vacc…

This study checks how well the ABRYSVO® vaccine protects infants from severe RSV when given to pregnant women. Researchers will look at hospital records from Argentina and Uruguay over several RSV seasons. The goal is to see if the vaccine reduces hospitalizations and severe illn…

This study reviews medical records to see how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV lung infections in adults 60 and older. Researchers will analyze existing health data from routine doctor visits over several years. No new treatments or active participat…

This study tests a new Lyme disease vaccine (VLA15) in about 200 healthy adults aged 18 to 44. Participants receive five shots over two years—four of the vaccine and one of salt water—to see if different timing schedules are safe and produce a strong immune response. The goal is …

This study tests new versions of a vaccine to prevent severe diarrhea caused by the C. diff germ. Healthy adults aged 50 and older who have never had a C. diff infection will receive either a new vaccine formula, a previously studied formula, or a placebo. The goal is to see whic…

This phase 2 trial is testing a new pneumococcal vaccine (PG4) in about 605 healthy infants to see if it is safe and triggers a strong immune response. Infants will receive four doses starting at 2 months old, and the new vaccine will be compared to existing vaccines like Prevnar…

This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious lung infections in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries, comparing those who got the vaccine to those who did not. T…

This study monitors the safety of the PREVENAR 20 vaccine in 1,100 infants aged 2 to 6 months in Japan. Infants receive four doses as part of routine care, and researchers track any side effects. The goal is to ensure the vaccine is safe for widespread use.

This study tests a new vaccine that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 200 healthy Chinese adults, children, and infants will receive the vaccine to see if it is safe and how well it triggers an immune respon…

This study looks at how well the ABRYSVO vaccine, given to pregnant women, protects their babies from RSV, a leading cause of severe lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in western Pennsylvania over several RSV seasons…

This study is checking the safety of the Abrysvo RSV vaccine in adults aged 60 and older in everyday medical practice in Japan. About 1100 people who get the vaccine will be watched for side effects for 28 days. The goal is to confirm the vaccine is safe for older adults.

This Phase 3 study tests whether a single dose of Pfizer's RSV vaccine (RSVpreF) can prevent lower respiratory tract illness caused by RSV in adults aged 60 and older. Over 38,800 participants across multiple countries received either the vaccine or a placebo. The study also look…

This Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the …

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This study tests a daily oral medication called ritlecitinib in children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 208 children will receive either a higher dose, lower dose, or placebo for 6 months. The goal is to see if the drug …

This study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…

This study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…

This study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder. The therapy delivers a working gene to help the body produce a clotting protein called Factor IX. Researchers will track how many bleeding episodes participants have …

This study tests a new drug called MET097, given as a shot, to help people with obesity or overweight lose weight. After 12 weekly doses, participants switch to monthly shots for up to 64 weeks. The trial compares four different dose schedules against a placebo to see which works…

This early-stage study by Pfizer tests a new drug called PF-07868489. First, it will be given to healthy volunteers to check safety and how the body processes it. Then, people with pulmonary arterial hypertension (PAH) will receive repeated doses over 24 weeks to see if it helps …

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,035 adults will be randomly assigned to either the new …

This phase 2 trial is testing a drug called elranatamab in 187 people with multiple myeloma whose cancer has not responded to at least three other types of treatment. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many patie…

This study tests a one-time gene therapy (PF-07055480) in 77 adult men with moderately severe to severe hemophilia A. The goal is to see if the treatment can reduce or prevent bleeding episodes compared to their usual factor VIII infusions. Participants receive a single IV dose a…

This study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants had already taken part in earlier studies and will continue taking etrasimod for up to 2 years. The goal is to see if the drug can …

This study tests a gene therapy (PF-06838435) for people with severe hemophilia B, a bleeding disorder. The therapy uses a harmless virus to deliver a working gene for clotting factor IX. Researchers are following 21 participants long-term to see if it is safe and reduces bleedin…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…

This study tests two oral medications, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to standard treatments. The goal is to see if the combination is safe and can shrink or control the cancer. P…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…

This study is checking the safety of the drug BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL). The 10 participants have already been treated and are being watched for side effects, especially liver problems. The goal is to better …

This Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…

This Phase 3 trial tests whether elranatamab, an immune-boosting drug, works better than lenalidomide at preventing multiple myeloma from returning in patients who have just had a stem cell transplant. About 854 participants will receive either elranatamab injections or lenalidom…

This early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer. About 107 participants with untreated, metastatic …

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a BRAF gene mutation. About 257 adults with untreated, advanced or spreading…

This study is monitoring 110 adults in Korea who are taking Vyndamax (tafamidis) for a rare heart condition called ATTR-CM. The goal is to track side effects and see how well the drug works over 10 years in everyday medical practice. Researchers will check heart function and symp…

This study tracks the safety of Hympavzi (marstacimab) in 50 people with hemophilia A or B who do not have inhibitors. Participants receive weekly injections to help control bleeding. The main goal is to monitor any side effects in real-world use.

This study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…

This study allows people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from crizotinib in a previous Pfizer study to keep receiving the drug after that study ends. About 27 participants will continue treatment while doctors monitor for side effects. The goal …

This study tracks the safety and effectiveness of CIBINQO (abrocitinib) tablets in over 1,100 Japanese patients with atopic dermatitis (eczema) under real-world medical practice. Researchers will monitor side effects, treatment dropouts, and skin clearance over time. The goal is …

This Phase 3 trial is testing an experimental oral drug called ARV-471 against a standard injectable drug, fulvestrant, in people with a common type of advanced breast cancer (ER+/HER2-). The study includes 624 participants whose cancer has worsened after prior hormone-based trea…

This early-stage study tests the safety of tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancer that has worsened after standard treatments. Researchers will monitor side effects and how the drug moves through the body. The goal is to s…

This study tests a new oral drug, ARV-471, combined with ribociclib in adults with advanced or metastatic ER+ breast cancer that has stopped responding to previous treatments. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. Participants …

This study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 o…

This study tests a gene therapy called PF-06939926 in 114 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. Two-thirds receive the gene therapy, while one-third get a placebo, but can switch to the real treatment after one year. The main goal is to see…

This study tests two oral drugs, vepdegestrant and PF-07220060, in people with advanced or metastatic ER+/HER2- breast cancer that has stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink tumors. Participants take the pills at home …

This phase 2 trial tests a new drug called PF-07220060 combined with fulvestrant against standard treatments in 333 adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has worsened after prior CDK4/6 inhibitor therapy. Half receive the experimental co…

This study tests a new oral drug, vepdegestrant, combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 37 adults will take both pills daily at home, with clinic visits every 4 weeks, to see if the comb…

This Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination w…

This study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in over 500 children aged 3 and older with growth hormone deficiency in Korea. Researchers will monitor side effects and growth changes over 6 years during routine medical care. The treatment he…

This phase 3 trial tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment helps control high-risk non-muscle invasive bladder cancer better than BCG alone. Over 1,000 participants are enrolled, with some receiving the combination and others BCG only. The…

This phase 2 trial tests whether adding tucatinib to standard drugs trastuzumab and capecitabine can shrink tumors in people with advanced HER2+ breast cancer who have already tried several treatments. About 66 participants will receive the three-drug combination. The main goal i…

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side ef…

This study is monitoring the safety and effectiveness of the drug Elranatamab in 150 Korean adults with multiple myeloma that has returned or not responded to at least three prior treatments. Researchers are tracking side effects and how well the drug controls the cancer in every…

This phase 3 study compares two drugs, lorlatinib and crizotinib, as the first treatment for people with advanced ALK-positive non-small cell lung cancer. About 296 patients who have not had prior treatment will receive either drug. The main goal is to see if lorlatinib delays ca…

This study provides continued access to the cancer drug palbociclib (IBRANCE) for up to 35 patients with breast or head and neck cancer who have already benefited from it in earlier Pfizer trials. Participants will keep taking their current treatment combination, which may includ…

This study is testing the safety of a drug called ATGAM in one patient with moderate to severe aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. The patient receives ATGAM by IV for 4 days and is monitored for 24 weeks for side effects. The goal …

This study looks at the safety of the drug TALZENNA in people with a specific type of breast cancer (BRCA mutation-positive, HER2-negative) that cannot be surgically removed or has come back after previous chemotherapy. Only 3 participants who have not used TALZENNA before will r…

This study tracks the safety of the drug TALZENNA in one man with a specific type of advanced prostate cancer that has a BRCA gene mutation and no longer responds to hormone therapy. The participant takes TALZENNA as prescribed and is monitored for side effects for up to a year. …

This study looks at the long-term safety and effectiveness of the drug elranatamab in people with relapsed and refractory multiple myeloma, a type of blood cancer that has not responded to other treatments. The study tracks side effects like cytokine release syndrome and nerve-re…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This study follows children with growth hormone deficiency who are starting Ngenla for the first time. Researchers will monitor their growth and any side effects over several years, until November 2027. The goal is to understand the long-term safety and effectiveness of this dail…

This study checks how well the RSV vaccine (ABRYSVO) works when given to pregnant women to protect their babies from severe RSV illness. Researchers will look at health records of infants hospitalized with breathing problems in Australia. They want to see if vaccinated moms' babi…

This study tested whether a nasal spray called zavegepant could relieve migraine pain within 2 hours. Adults with migraines for at least a year were to use the spray at home for up to 4 attacks. The study was withdrawn before enrolling participants, so no results are available.

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This early-stage study is testing a new tablet version of the COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how much of the drug gets into the blood when taken as a whole tablet, dispersed in water, or with food. The goal is to compare the new tablet to…

This early-stage study in 16 healthy adults aims to compare how well a new film-coated tablet of the experimental drug PF-07799933 is absorbed versus an older tablet form. It also checks whether taking the drug with a high-fat meal or with an acid-reducing medication changes drug…

This early-stage study looks at whether the antifungal itraconazole changes how the body handles a new drug called PF-08642534. Fourteen healthy adults will take the study drug with and without itraconazole. The goal is to see how the drug levels change, not to treat any disease.

This early-stage trial compares a new orally disintegrating tablet (ODT) of tafamidis to the standard capsule in 15 healthy adults. Participants receive single doses of each form under fasting conditions to measure drug levels in the blood. The goal is to see if the ODT works the…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study looks back at medical records of 50 Chinese adults with advanced ALK-positive non-small cell lung cancer who received lorlatinib as their first treatment. Researchers want to learn about patient characteristics, such as age and smoking history, and how the drug is used…

This study uses anonymous health insurance records from Germany to learn more about a rare heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers will look at survival rates, hospital visits, and how common the disease is. No new treatments are…

This early-stage study tests a single dose of the experimental drug PF-08653944 in 54 overweight or obese adults. Researchers want to see how the drug is absorbed when injected into the abdomen, thigh, or upper arm. The study also monitors safety through blood tests and vital sig…

This study observes how 4,000 adults with ulcerative colitis are treated in real-world clinics, not in a controlled trial. Researchers will analyze prescription patterns and outcomes to create an updated treatment flowchart. The goal is to improve understanding of which therapies…

This study looks at how well the drug ritlecitinib works for people with severe alopecia areata (a condition causing patchy or total hair loss) in real-world settings, not just in controlled trials. Researchers will review medical records of about 300 patients aged 12 and older w…

This study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …

This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…

This study follows 319 people under 21 who developed heart inflammation (myocarditis or pericarditis) within 21 days of receiving the Comirnaty (Pfizer) COVID-19 vaccine. Researchers will monitor their heart function with imaging tests for up to 5 years to see if there are lastin…

This study follows 250 adults in the UK who already use rimegepant for migraine attacks. Over 12 weeks, they report how quickly the drug eases pain and other symptoms. The goal is to see how consistently rimegepant works in everyday life.

This study is monitoring the safety of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in 12,000 people in South Korea who received the vaccine as part of routine care. Researchers are tracking side effects like sore arms or fever within a week of each dose, as well as any other …

This study follows over 1,400 patients in Germany and Austria with HR+/HER2- advanced breast cancer who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overal…

This study follows about 1,000 adults in the U.S. who test positive for COVID-19 or influenza. Participants fill out surveys about their symptoms and quality of life over six months. The goal is to understand how these illnesses affect daily activities and whether COVID-19 vaccin…

This early-stage study tests a new medicine called PF-07999415 in healthy adults aged 18 to 65. Participants receive a single shot and stay in a clinic for 2 weeks for monitoring. The goal is to check safety and how the body processes the drug, not to treat any disease. Results w…

This early-stage trial in 12 healthy adults looks at how the antifungal drug itraconazole changes the way the body processes Pfizer's experimental drug PF-07248144. Participants take PF-07248144 alone and then again with itraconazole to compare drug levels and safety. The goal is…

This study is a disease registry that collects information from routine medical care of about 350 adults diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments received, and ho…

This early-stage study tests the safety of PF-08049820, a medicine being developed for eczema (atopic dermatitis), in about 71 healthy adults. Participants will take single or multiple doses of the drug or a placebo, and researchers will monitor how the body processes it and whet…

This study monitors the safety of the Comirnaty (Bretovameran) COVID-19 vaccine in 660 Korean participants aged 12 and older. Researchers will track side effects like injection site reactions and serious adverse events for up to 28 days after each dose. The goal is to identify an…

This study looks at whether the migraine medication rimegepant is safe to take during pregnancy. Researchers will compare pregnancy outcomes in women who took rimegepant to those who did not. The study includes women aged 16 to 49 with migraine. However, only one person has been …

This Pfizer study aimed to check if new combination tablets of nirmatrelvir/ritonavir (the drug in Paxlovid) work the same as the current marketed version. About 28 healthy adults were to receive single doses of different tablet forms under fasting conditions. However, the study …

This study looks at how a new medicine (PF-08049820) is processed by the body when taken alone or with another drug (rabeprazole). It involves 18 healthy Chinese adults aged 18-65. Participants take both medicines by mouth, and blood samples are collected to measure drug levels. …

This study looks at how a new medicine called PF-08049820 changes the way birth control pills, a sedative, and a blood thinner move through the body. It involves 16 healthy adult women who will take the drugs alone and then with PF-08049820. The results will help plan future stud…

This study looks at how Palbociclib and other CDK4/6 inhibitors are actually used in patients with a common type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records from routine care to see how long patients stay on treatment and whether it d…

This study looks at how well the yearly updated Pfizer COVID-19 vaccine works in adults and children. Instead of giving anyone the vaccine, researchers will analyze existing insurance claims and state vaccine records. They will compare people who got the vaccine to those who did …